These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31338174)

  • 21. Nasal closure for the treatment of epistaxis secondary to hereditary hemorrhagic telangiectasia.
    Sena Esteves S; Cardoso C; Silva A; Abrunhosa J; Almeida E Sousa C
    Acta Otorrinolaringol Esp; 2016; 67(6):345-348. PubMed ID: 27079134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hereditary haemorrhagic telangiectasia in a black adult male: case report.
    Kitonyi GW; Wambugu PM; Oburra HO; Ireri JM
    East Afr Med J; 2008 Aug; 85(8):412-6. PubMed ID: 19115559
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.
    Karnezis TT; Davidson TM
    Laryngoscope; 2011 Mar; 121(3):636-8. PubMed ID: 21344445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrin glue in initial treatment of epistaxis in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease).
    Vaiman M; Martinovich U; Eviatar E; Kessler A; Segal S
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):359-63. PubMed ID: 15166924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The minimal important difference of the epistaxis severity score in hereditary hemorrhagic telangiectasia.
    Yin LX; Reh DD; Hoag JB; Mitchell SE; Mathai SC; Robinson GM; Merlo CA
    Laryngoscope; 2016 May; 126(5):1029-32. PubMed ID: 26393959
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Epistaxis in Rendu-Osler-Weber disease treated with selective embolization--case report].
    Jarzabek M; Trojanowski P; Szajner M; Pyra K; Sojka M; Szczerbo-Trojanowska M
    Przegl Lek; 2012; 69(7):317-9. PubMed ID: 23276024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review on clinical management and pharmacological therapy on hereditary haemorrhagic telangiectasia (HHT).
    Zarrabeitia R; Albiñana V; Salcedo M; Señaris-Gonzalez B; Fernandez-Forcelledo JL; Botella LM
    Curr Vasc Pharmacol; 2010 Jul; 8(4):473-81. PubMed ID: 19485912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pazopanib effective for bevacizumab-unresponsive epistaxis in hereditary hemorrhagic telangiectasia.
    Parambil JG; Woodard TD; Koc ON
    Laryngoscope; 2018 Oct; 128(10):2234-2236. PubMed ID: 29451965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hereditary Hemorrhagic Telangiectasia: A Rare Cause of Anemia.
    Jan W; Tameez Ud Din A; Chaudhary FMD; Tameez-Ud-Din A; Nawaz F
    Cureus; 2019 Aug; 11(8):e5349. PubMed ID: 31602353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia.
    Rohrmeier C; Sachs HG; Kuehnel TS
    Eur Arch Otorhinolaryngol; 2012 Feb; 269(2):531-6. PubMed ID: 21805356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of epistaxes in hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber disease) with tranexamic acid].
    Morales-Angulo C; Pérez del Molino A; Zarrabeitia R; Fernández A; Sanz-Rodríguez F; Botella LM
    Acta Otorrinolaringol Esp; 2007 Apr; 58(4):129-32. PubMed ID: 17428407
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy assessment of current treatment options for epistaxis in HHT.
    Dür C; Anschuetz L; Negoias S; Bulut OC; Angelillo-Scherrer A; Caversaccio M
    Eur Arch Otorhinolaryngol; 2021 Nov; 278(11):4321-4328. PubMed ID: 33661356
    [TBL] [Abstract][Full Text] [Related]  

  • 33. European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?
    Dupuis-Girod S; Shovlin CL; Kjeldsen AD; Mager HJ; Sabba C; Droege F; Fargeton AE; Fialla AD; Gandolfi S; Hermann R; Lenato GM; Manfredi G; Post MC; Rennie C; Suppressa P; Sure U; ; Buscarini E
    Eur J Med Genet; 2022 Oct; 65(10):104575. PubMed ID: 35940549
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A natural obturator in hereditary haemorrhagic telangiectasia.
    Soni-Jaiswal A; Woolford TJ
    J Laryngol Otol; 2009 Jun; 123(6):695-6. PubMed ID: 19275781
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term experience with intranasal bevacizumab therapy.
    Steineger J; Osnes T; Heimdal K; Dheyauldeen S
    Laryngoscope; 2018 Oct; 128(10):2237-2244. PubMed ID: 29469958
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hereditary HaemorrhagicTelangiectasia--A Rare Cause of Severe Anaemia.
    Deshpande P; Bhat S; Karmarkar A
    J Assoc Physicians India; 2014 Dec; 62(12):48-51. PubMed ID: 26259423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients.
    Pagella F; Colombo A; Matti E; Giourgos G; Tinelli C; Olivieri C; Danesino C
    Am J Rhinol Allergy; 2009; 23(1):52-8. PubMed ID: 19379613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab as rescue treatment for severe recurrent gastrointestinal bleeding in hereditary hemorrhagic telangiectasia.
    Lupu A; Stefanescu C; Treton X; Attar A; Corcos O; Bouhnik Y
    J Clin Gastroenterol; 2013 Mar; 47(3):256-7. PubMed ID: 23164683
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful therapy with bevacizumab in a case of hereditary hemorrhagic telangiectasia.
    Kochanowski J; Sobieszczańska M; Tubek S; Żurek M; Pawełczak J
    Hum Vaccin Immunother; 2015; 11(3):680-1. PubMed ID: 25839219
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Rare Case of Hereditary Hemorrhagic Telangiectasia: A Case Report.
    Khan AR; Waqar S; Wazir MH; Arif A
    Cureus; 2022 Apr; 14(4):e24517. PubMed ID: 35651452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.